# Bionyra Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bionyra-pharma

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.bionyra.com
- Total disclosed funding: $324M
- Investors on record: 7

## About

Based in France, Bionyra Pharma SAS is a biotechnology company focused on developing innovative biologics for treating severe immune-mediated inflammatory diseases through advanced monoclonal and bispecific antibody therapies.Bionyra Pharma SAS, established in 2025 and headquartered in Paris, France, specializes in creating biologics for immune-mediated inflammatory conditions. The company has secured funding through two deals, including a Series A round that raised EUR 143.00 mn from investors such as Apollo Health Ventures and Sanofi Ventures, marking a significant step in its growth trajectory.Bionyra Pharma specializes in the development of next-generation biologics focused on severe immune-mediated inflammatory diseases. The company’s core product offerings include a range of monoclonal antibodies and bispecific antibodies designed to target novel immune pathways, with initial applications in atopic dermatitis and inflammatory bowel disease (IBD). Notable products include BYN-002, a TL1A monoclonal antibody that incorporates half-life extension (HLE) technology, and BYN-003, a bispecific antibody targeting both TL1A and IL-23. By offering innovative therapies that reduce dosing frequency and address multiple disease drivers, Bionyra aims to provide significant improvements in patient outcomes. The company holds exclusive global rights for its products outside of Greater China, thereby targeting a wide range of international markets where immune-mediated diseases are prevalent, including North America and Europe.Bionyra Pharma’s revenue structure is primarily derived from partnerships and collaborations with biopharmaceutical companies, as well as potential future product sales. The company’s financial model is centered around the development and commercialization of its proprietary biologics, including its flagship products BYN-002, BYN-003, and BYN-001. In these transactions, Bionyra may engage in licensing agreements or strategic collaborations that facilitate the distribution and commercialization of its therapies to healthcare providers and institutions. The pricing for these products is set based on market conditions and the value provided to healthcare systems, with the objective of delivering effective treatments for patients suffering from chronic inflammatory conditions. The company’s financing efforts, including an oversubscribed Series A round, indicate investor confidence in its potential for generating revenue through successful clinical development and market entry of its innovative products.Bionyra Pharma plans to introduce new products targeting severe immune-mediated diseases, with specific upcoming releases related to its monoclonal and bispecific antibodies. The company is also looking to expand into markets across North America and Europe by 2026. Recent funding from the Series A round will be utilized to support the clinical development and commercialization of its product pipeline, enhancing its capacity to reach patients with chronic inflammatory conditions.

## Funding rounds

- Round, Oct 16, 2026, $160M
- Series A, Jun 22, 2026, $164M — Sofinnova Partners, Vives, Sanofi Ventures, Arkin Capital, Apollo Health Ventures, Jeito Capital, Sixty Degree Capital

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Vives (https://capitalatlas.ai/funds/vives) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Series A
- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Series A
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series A
- Sixty Degree Capital (https://capitalatlas.ai/funds/sixty-degree-capital) — Series A